摘要
目的探讨依折麦布联合吉非罗齐治疗高脂血症的安全性和有效性。方法选择2014年3月至2016年3月在我院接受治疗的高脂血症患者128例,以随机数字表法将其分为观察组和对照组,每组64例。对照组给予吉非罗齐治疗,观察组采用依折麦布联合吉非罗齐治疗,疗程为1个月。观察两组患者治疗前后总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白-胆固醇(HDL-C)以及低密度脂蛋白-胆固醇(LDL-C)等水平的变化。结果观察组总有效率为93.75%(60/64),明显高于对照组的76.56%(49/64)(P<0.05)。治疗后两组TC、TG和LDL-C均较治疗前显著降低,HDL-C显著升高,但观察组变化更显著,两组比较差异均有统计学意义(P<0.05)。观察组治疗后不良反应发生率为9.38%,对照组为15.63%,两组比较差异无统计学意义(P>0.05)。结论依折麦布联合吉非罗齐能在短时间内有效治疗高脂血症,降脂疗效明显优于单用吉非罗齐,且能同时降低TG和TC,安全性高。
Objective To explore the safety and efficacy of ezetimibe combined with gemfibrozil in the treatment of hyperlipidemia.Methods Totally 128 cases of hyperlipidemia patients treated in our hospital from March2014 to March 2016 were selected and divided into observation group and control group,with 64 cases in each group by the table of random number.Patients in control group only used gemfibrozil for treatment,and patients in observation group were treated with ezetimibe and gemfibrozil,the course of treatment being 1 month.Before and after treatment,the indexes of total cholesterol(TC),triglyceride(TG).high density lipoprotein cholesterol(HDL-C) and low density lipoprotein cholesterol(LDL-C) of the two groups were observed and compared.Results The total effective rate of observation group was higher than that of control group(93.75%vs.76.56%,P〈0.05).After treatment,TC,TG and LDL-C were decreased and HDL-C was increased significantly in the two groups,and the changes in observation group were more significant than control group.there being significant difference between the two groups(P〈0.05).After treatment,the adverse reaction rate of observation group and control group was 15.63%and 9.38%.there being significant difference between the two groups(P〈0.05).Conclusion Ezetimibe combined with gemfibrozil is effective in the treatment of hyperlipidemia in a short period of time with high safety,the lipid-lowering effect is better than the single use of gemifibrozil,and it can also reduce TG and TC.
出处
《实用药物与临床》
CAS
2016年第11期1357-1359,共3页
Practical Pharmacy and Clinical Remedies
基金
江苏省苏州市科技计划项目申报书(应用基础研究计划-医疗卫生部分)